ASCO

Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article

This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014.
Read Article

A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse.
Read Article

This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma.
Read Article

The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM).
Read Article

Benjamin P. Levy, MD, reviews current and emerging roles for agents that target the VEGF axis in advanced non–small-cell lung cancer and expresses his belief that a lot of work needs to be done to define the optimal space for these drugs.
Read Article

Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.
Read Article

Benjamin P. Levy, MD, provides an overview of evolving strategies to manage patients with acquired TKI resistance in advanced non–small-cell lung cancer with a focus on identifying and treating t790m.
Read Article

Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
Read Article


Page 3 of 19